Background: Recent data are lacking about the number of patients with angiotensin-converting enzyme inhibitor (ACEI)-induced angioedema who present to the emergency department (ED). Current management of the condition and clinical outcomes also are not known. Objective: To describe the clinical epidemiology of ACEI-induced angioedema in patients who present to the ED. Methods: We performed a medical record review of ACEI-induced angioedema in patients who presented to 5 EDs in the Emergency Medicine Network. A structured data abstraction form was used to collect each patient's demographic factors, medical history, and details about the angioedema that prompted the ED visit. The medical record review also focused on treatment provided in t...
AIM: The aim of the present study was to describe the occurrence and determinants of angiotensin-con...
Objective. To asses a cohort of 105 consecutive patients with angiotensin converting enzyme-inhibito...
Background: Angiotensin-converting enzyme inhibitor–associated angioedema (ACEI-AAE) affects 0.1%-0....
BACKGROUND: Angioedema is an uncommon and poorly recognised adverse reaction to angiotensin converti...
Introduction: Upper airway angioedema is a life-threatening emergency department (ED) presentation w...
Fitzharris and Jordan report that angio-oedema occurs in 0.1-0.7% of all patients taking angiotensin...
BACKGROUND: Angioedema is an infrequent but potentially serious adverse effect of angiotensin conver...
Objectives/Hypothesis: Angioedema (AE) is a condition that may prompt a visit to an emergency depart...
Introduction: Angioedema represents self-limited, localized swelling of submucosal or subcutaneous t...
Background: Bradykinin-mediated angioedema (Bk-AE) can be life-threatening and requires specific tar...
Background: Angiotensin converting enzyme (ACE) inhibitor related angioneurotic edema or simply angi...
Background: Angioedema, a potentially fatal adverse event of angiotensin- converting enzyme inhibito...
Objectives: This study describes the occurrence of angioedema among patients initiating ACEI therapy...
Introduction: ACE inhibitors accounts for 8 % of all cases of angioneurotic edema and the overall in...
Angioedema is a rare but life-threatening side effect of angiotensin-converting enzyme inhibitor (AC...
AIM: The aim of the present study was to describe the occurrence and determinants of angiotensin-con...
Objective. To asses a cohort of 105 consecutive patients with angiotensin converting enzyme-inhibito...
Background: Angiotensin-converting enzyme inhibitor–associated angioedema (ACEI-AAE) affects 0.1%-0....
BACKGROUND: Angioedema is an uncommon and poorly recognised adverse reaction to angiotensin converti...
Introduction: Upper airway angioedema is a life-threatening emergency department (ED) presentation w...
Fitzharris and Jordan report that angio-oedema occurs in 0.1-0.7% of all patients taking angiotensin...
BACKGROUND: Angioedema is an infrequent but potentially serious adverse effect of angiotensin conver...
Objectives/Hypothesis: Angioedema (AE) is a condition that may prompt a visit to an emergency depart...
Introduction: Angioedema represents self-limited, localized swelling of submucosal or subcutaneous t...
Background: Bradykinin-mediated angioedema (Bk-AE) can be life-threatening and requires specific tar...
Background: Angiotensin converting enzyme (ACE) inhibitor related angioneurotic edema or simply angi...
Background: Angioedema, a potentially fatal adverse event of angiotensin- converting enzyme inhibito...
Objectives: This study describes the occurrence of angioedema among patients initiating ACEI therapy...
Introduction: ACE inhibitors accounts for 8 % of all cases of angioneurotic edema and the overall in...
Angioedema is a rare but life-threatening side effect of angiotensin-converting enzyme inhibitor (AC...
AIM: The aim of the present study was to describe the occurrence and determinants of angiotensin-con...
Objective. To asses a cohort of 105 consecutive patients with angiotensin converting enzyme-inhibito...
Background: Angiotensin-converting enzyme inhibitor–associated angioedema (ACEI-AAE) affects 0.1%-0....